Acer Medical: VeriOsteo OP Obtains Medical Device Approval from Indonesia’s Ministry of Health

TAIPEI, Oct. 10, 2024 /PRNewswire/ — Acer Medical announced that its AI-assisted bone mineral density abnormalities screening software, VeriOsteo OP, has obtained a medical device certificate from Indonesia’s Ministry of Health. This marks the second product to receive registration approval, following the certification of the VeriSee DR, an AI-assisted diagnostic solution for diabetic retinopathy VeriSee DR.


AI-Assisted Bone Mineral Density Abnormality Screening Software – VeriOsteo OP

VeriOsteo OP analyzes bone mineral density (BMD) through X-ray images, calculates the bone mineral density (BMD) and to predict T-score and assists doctors in assessing potential BMD abnormalities. The software offers both medical professionals and patients with quick results and appropriate treatment options.

Indonesia has a population of more than 200 million, making it the fourth-largest country in the world. Their elderly population of approximately 16 million is susceptible to abnormal bone density. Due to low awareness of the disease, many forego or delay seeking medical treatment, missing the critical period for early intervention.

Acer Medical, a subsidiary of the Acer Group, specializes in leveraging artificial intelligence (AI) and software development to produce medical imaging devices for early and preventive disease detection. The company is dedicated to developing smart medical software and hardware solutions based on AI-driven medical imaging technologies to enhance the diagnostic process. To date, Acer Medical’s AI medical imaging products have obtained 12 medical device certifications in Taiwan and have been successfully implemented in over 300 medical institutions.

Subscribe on LinkedIn

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.